RxDoctor Payments Data

Jay St John, MD

Geriatric Medicine · New Orleans, LANPI 1578820619

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $310 of the $350 with a category attached, or 88.6%. It is spread thinly across 14 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations.

$350in general payments, 2019–2025

Across 24 payments — averaging $14.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$65
  • Gilead$40
  • AbbVie$39
  • Novo Nordisk$34
  • GSK$32
  • Merck$26
  • plus $114 from 8 others

What the payments were for

  • Food & beverage$31089%
  • Education$4011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$350 in reported general payments places this provider in the 75th percentile of 40 geriatric medicine providers in Louisiana.

See all geriatric medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$125,977
Medicare patients
347
Services billed
1,206

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,571$471,852
IngrezzaValbenazine Tosylate107$392,839
JanuviaSitagliptin Phosphate417$121,862
OzempicSemaglutide110$113,306
TrulicityDulaglutide104$106,696
JardianceEmpagliflozin174$53,868
Trelegy ElliptaFluticasone/Umeclidin/Vilanter73$50,352
XifaxanRifaximin26$40,452
Atorvastatin Calcium2,384$34,574
EntrestoSacubitril/Valsartan94$33,036
GemtesaVibegron109$26,972
TradjentaLinagliptin84$23,504
AptiomEslicarbazepine Acetate18$22,959
MyrbetriqMirabegron97$22,913
Memantine Hcl659$22,865

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$26$121,862417 claims
Novo NordiskOzempic$34$113,306110 claims
Lilly USA, LLCTrulicity$11$106,696104 claims
Boehringer IngelheimJardiance, Tradjenta$14$77,373258 claims
GSKTrelegy Ellipta, Breo Ellipta$32$63,808105 claims
AbbVieLinzess, Lumigan$39$26,29649 claims
AstraZenecaBreztri Aerosphere, Farxiga$21$22,00050 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 40 geriatric medicine providers in Louisiana.

Other geriatric medicine in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →